Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors.

This study reviewed a new approach to cancer treatment using medications called PARP inhibitors. PARP inhibitors are drugs that target cancer cells with specific genetic weaknesses, particularly those that can't repair their DNA properly. While these medications have shown promise, they face challenges including drug resistance, limited effectiveness in only certain tumor types, and blood-related side effects. Researchers have been developing "dual inhibitors" that target PARP plus another cancer pathway at the same time within a single drug. This approach aims to overcome the limitations of current treatments while reducing the toxicity that comes from taking multiple separate medications. The review examined how these dual inhibitors work, which targets they combine with PARP, and how their chemical structures affect their effectiveness. The goal is to create more powerful cancer treatments with fewer side effects. While this research focuses on pharmaceutical drug development rather than integrative therapies, patients undergoing cancer treatment may benefit from complementary approaches. Acupuncture has been studied as supportive care during conventional cancer treatment, particularly for managing chemotherapy side effects like nausea, fatigue, and neuropathy. If you're considering acupuncture as part of your cancer care plan, work with your oncology team and seek a qualified practitioner certified in oncology acupuncture.

This review examines the development of PARP-based dual inhibitors as targeted anticancer agents. PARP inhibitors exploit synthetic lethality in homologous recombination (HR)-deficient tumors but face limitations including resistance mechanisms, HR-dependency, and hematological toxicity. Dual-target PARP inhibitors combine PARP inhibition with complementary pathways in a single molecular entity, addressing pharmacokinetic complexities and cumulative toxicity of combination regimens. The review analyzes target selection rationale, structure-activity relationships, and synergistic mechanisms of action. This is a theoretical drug development review without clinical trial data or patient outcomes. Clinical relevance for acupuncture practitioners: Patients undergoing PARP inhibitor therapy may experience hematological and other toxicities that could benefit from integrative supportive care. Acupuncture may provide adjunctive symptom management during targeted cancer therapy, though this review does not address complementary medicine approaches. Evidence-based protocols for chemotherapy-support acupuncture may be applicable to patients receiving these novel targeted agents.